April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Evaluation of visual function in ocular hypertension: PROG-F3 study
Author Affiliations & Notes
  • Maxime Delbarre
    Department of Ophthalmology, Military Hospital of Val-de-Grace, Paris, France
  • Jean-Marie Giraud
    HIA Saint-Anne, Toulon, France
  • Florent Aptel
    CHU Grenoble, Grenoble, France
  • Hussam El Chehab
    Department of Ophthalmology, Military Hospital of Val-de-Grace, Paris, France
  • Jean-Remi Fenolland
    Department of Ophthalmology, Military Hospital of Val-de-Grace, Paris, France
  • Marie Maréchal
    Department of Ophthalmology, Military Hospital of Val-de-Grace, Paris, France
  • Anne-Florence Marill
    Department of Ophthalmology, Military Hospital of Val-de-Grace, Paris, France
  • Franck May
    Department of Ophthalmology, Military Hospital of Val-de-Grace, Paris, France
  • Jean-Paul G Renard
    Department of Ophthalmology, Military Hospital of Val-de-Grace, Paris, France
  • Footnotes
    Commercial Relationships Maxime Delbarre, None; Jean-Marie Giraud, None; Florent Aptel, None; Hussam El Chehab, None; Jean-Remi Fenolland, None; Marie Maréchal, None; Anne-Florence Marill, None; Franck May, None; Jean-Paul Renard, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5632. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maxime Delbarre, Jean-Marie Giraud, Florent Aptel, Hussam El Chehab, Jean-Remi Fenolland, Marie Maréchal, Anne-Florence Marill, Franck May, Jean-Paul G Renard; Evaluation of visual function in ocular hypertension: PROG-F3 study. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5632.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Purpose of this multicentric study is to analyze progression of visual field indices of patients treated for ocular hypertension (OHT).

Methods: This prospective study concerned 23.5% of a multicentric cohort (104 eyes of 441). These eyes were monitored and treated for OHT followed up at least 9.7+/-1.65yrs. Every patients underwent every 6 months a complete eye examination and a reproducible visual field testing (Humphrey Field Analyser, SITA-Standard 24-2, Carl Zeiss Meditec) to eliminate any other ocular pathology. At the end of follow-up, patients who developed a POAG were included in evolutive group and patients without functional or structural deficits were considered stable. The following parameters were analyzed: MD, VFI and their rate of progression. Statistical analysis compared populations by a Student t-test and a diagnostic performance was assessed by sensitivity (Se), specificity (Sp) and area under receiver operating characteristic curve (AUROC) of all parameters.

Results: Evolutive group included 46 eyes (44.2%) and stable group included 58 eyes (55.7 %). Rate of progression of MD (dB/yr) for stable and evolutive groups were respectively -0.007 (95%CI [-0.024 ; 0.011]) and -0.285 (95%CI [-0.361 ; -0.209]) (p <0.001). Rate of progression of VFI (%/yr) for stable and evolutive groups were respectively -0.026 (95%CI [-0.042 ; -0.009]) and -0.407 (95%CI [-0.627 ; -0.187]) (p=0.001). Initial MD (dB) at beginning of follow up for stable and evolutive groups were 1.139 (95%CI [0.997 ; 1.313]) and 0.616 (95%CI [0.488 ; 0.744]) (p<0.001). Initial VFI (%) were 99.793 (95%CI [99.675 ; 99.911]) and 99.304 (95%CI [99.098 ; 99.511]) (p<0.001). AUC were, respectively, for MD and VFI rate of progression and MD, VFI indices : 0.966, 0.827, 0.731, 0.702. The cut off value of AUROC were respectively for MD rate of progression, for VFI rate of progression, for MD, and VFI and: -0.100 dB/yr indices (Se=93.5%, Sp=91.4%), -0.143 %/yr (Se=54.3%, Sp=98.3%), 1.02 dB (Se=89.1%, Sp=50.0%) and 99% (Se=81.0%, Sp=58.7%).

Conclusions: MD and VFI rate of progression in OHT evolutive group were higher than in group of patients remained stable. This study reports a higher diagnostic power for MD rate of progression with a cut off of -0.1 dB/year. It could be used to screen OHT patients at risk of POAG. These preliminary results must be completed by further analysis in this multicenter study.

Keywords: 758 visual fields  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×